News & Events
- May 18, 2018
May 7, 2018
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and, specifically,...
April 26, 2018
CPTR Newsletter – April 2018CPTR Newsletter – April 2018 In this issue: ReSeqTB to be Adopted for WHO Surveillance of Drug-Resistant TB New Collaborations Expand TB-PACTS Database and Leverage Data for Analyses CPTR Workgroup Works to Advance Regulatory Qualification of LAM, a Promising New Biomarker TB-PBPK Model Progresses Toward EMA and FDA Qualification TB-ReFLECT Update: A Collaborative Effort...
April 16, 2018
Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease BiomarkersTucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path Institute (C-Path) a grant to support a Crohn’s disease biomarker pre-consortium. The pre-consortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn’s disease. Currently,...
February 12, 2018
Tucson-based Critical Path Institute emerging as top drug-research organizationPresident and CEO Dr. Martha Brumfield was recently interviewed by the Arizona Daily Star for a profile on C-Path published February 11. Dr. Brumfield discusses C-Path’s local ties,expanding global reach, and its recent successes, as well as its groundbreaking collaborative research model. The story outlines the work of C-Path’s consortia in the areas of biomarker...